IO Biotech shares fall 13.66% intraday as company announces exploration of strategic alternatives.

IO Biotech (NASDAQ:IOBT) fell 13.66% intraday following its announcement on January 21, 2026, that the company is exploring strategic alternatives. The news, reported by multiple outlets including au.investing.com and GlobeNewswire, triggered immediate investor concern over potential corporate restructuring, divestitures, or other value-uncertain moves. This development overshadowed earlier positive updates, such as the December 2025 publication of MM1636 trial results and November 2025 pre-clinical data presentations, which had briefly supported the stock. The exploration of strategic alternatives typically signals operational or ownership uncertainty, prompting selling pressure as investors reassess risk. No other recent news events directly correlated with the intraday decline, which aligns with the bearish sentiment from the strategic review announcement.